In this webinar, the unique mechanism of action for allosteric tyrosine kinase 2 (TYK2) inhibitors compared with Janus kinase inhibitors will be reviewed. The efficacy and safety data for TYK2 inhibitors in psoriasis and psoriatic arthritis will be presented along with relevant data in hard-to-treat psoriasis, response by baseline weight, and response in biologic experienced patients to inform treatment decisions. A case-based approach will illustrate how TYK2 inhibition can be incorporated into psoriasis treatment.
- Provider:Paradigm Medical Communications, LLC
- Activity Link: https://ce.paradigmmc.com/a/GSBNCC
- Start Date: 2024-09-30 05:00:00
- End Date: 2024-09-30 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 53525.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest